Sarah Boyce - 26 Jun 2025 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role: Director
Signature: /s/ Peter Slover, Attorney-in-Fact
Issuer symbol: CTNM
Transactions as of: 26 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 26 Jun 2025, 17:50:00 UTC
Previous filing: 21 Mar 2025
Next filing: 29 Aug 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Boyce Sarah	Director	3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO	/s/ Peter Slover, Attorney-in-Fact	26 Jun 2025	0001629383

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTNM	Stock Option (right to buy)	Award	$0	+14,750		$0.000000	14,750	26 Jun 2025	Class A Common Stock	14,750	$4.01	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.

Content

Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"), pursuant to the Issuer's Non-Employee Director Compensation Program, as amended, which states that upon the conclusion of each regular annual meeting of the Company's stockholders, each non-employee director who continues to serve as a member of the Company's Board of Directors thereafter will automatically be granted a stock option under the Plan for 14,750 shares of the Company's Class A Common Stock. Option will vest in full on the earlier of (i) June 26, 2026, the one-year anniversary of the date of grant, or (ii) the next regular annual meeting of stockholders, subject to the Reporting Person's continuous service.